EXPERIMENTAL THERAPY OF CHRONIC COLITIS IN RHESUS MACAQUES

恒河猴慢性结肠炎的实验治疗

• 批准号: 6277861
• 负责人: NICHOLAS WILLIAM LERCHE
• 金额: $ 4.77万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-05-01 至 1999-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6277861
• 关键词: Mammalia; Primates; biological products; drug /agent; intestines

Significance Chronic colitis and diarrhea is a well recognized syndrome in a small proporitonof rhesus macaques maintained in captivity. The etiology and pathogenesis of this syndrome is not well understood, although artificial weaning of young macaques has been identified as a risk factor for development of chronic colitis in epidemiologic studies. As currently defined, this syndrome is includes persistence of diarrhea and colitis in the absence of any identifiable enteric pathogen. Objective This spontaneously occurring disease is being evaluated as a model of inflammatory bowel disease (IBD) in humans, and for testing of novel therapeutic compounds for the treatment of IBD. Results Several novel compounds have been evaluated for efficacy in the treatment of chronic colitis in the rhesus model. One compound, GW-83X has shown potential as a therapeutic agent, achieving clinical improvement in treated animals. Future Directions GW-83X will be further evaluated at various dose levels. Additional compounds will also be evaluated using this macaque model system. KEYWORDS colitis, diarrhea

意义慢性结肠炎和腹泻是公认的 一个小比例的恒河猴综合征维持在 囚禁 本病的病因病机尚不清楚 理解，虽然人工断奶的年轻猕猴一直是 被确定为慢性结肠炎发展的危险因素， 流行病学研究。 根据目前的定义，这种综合征是 包括腹泻和结肠炎的持续存在， 可识别肠道病原体。 目的本研究目的在于探讨 疾病被评估为炎症性肠病的模型 (IBD)在人类中，并用于测试新的治疗化合物， IBD的治疗。 结果合成了几个新化合物， 在慢性结肠炎的治疗中评价疗效， 恒河猴模型 一种化合物GW-83 X显示出作为一种 治疗剂，在治疗的动物中实现临床改善。 未来方向GW-83 X将在各种剂量下进行进一步评价 程度. 其他化合物也将使用该方法进行评价。 猕猴模型系统。 关键词结肠炎、腹泻